Autorisation du vaccin COVID : erreurs ou complicités ?

Key statements

• The primary efficacy endpoint — PCR-confirmed symptomatic COVID — is biased because symptom-reporting is participant-driven and antipyretics (paracetamol etc.) were permitted, suppressing symptoms. ▶ 01:46
  Sources: Pfizer C4591001 Protocol
• Vaccine-group participants took antipyretics 3.5× more often than placebo-group participants. With suppressed symptoms came suppressed testing — and suppressed COVID case counts — artificially inflating the 95% headline. ▶ 02:36
  Sources: Pfizer C4591001 interim clinical study report (Dec 2020) — antipyretic use tables
• PCR-confirmed symptomatic COVID is not representative of real-world infection. Anti-nucleocapsid serology — which would have caught asymptomatic and undetected cases — was not used to define the endpoint. ▶ 05:05
  Sources: Pfizer C4591001 Protocol
• Pre-clinical monkey data and Phase 1-2 human data already showed neutralizing antibody decline after two months. In Phase 3, Pfizer performed no antibody titre measurement at three months — the time-point that would have shown waning protection. ▶ 05:39
  Sources: Pfizer C4591001 Protocol (immunogenicity schedule)
• Pfizer was already studying a booster dose in December 2020 — the same month it was telling the public a two-dose regimen would restore normal life. They knew protection wouldn't last. ▶ 06:46
  Sources: Pfizer booster sub-study protocol (Dec 2020 amendment to C4591001)
• GCP guidelines require extreme traceability (every data entry signed, audited server-room access, redundant air conditioning). All of that regulation, designed to protect trial participants and the public, was disregarded in the COVID trials. ▶ 11:11
  Sources: ICH-GCP guidelines
• The European Commission ordered 4.2 billion doses for 447 million Europeans — roughly 8-9 doses per person. The order itself proves Brussels knew, from the start, that boosters would be needed. ▶ 14:07
  Sources: EU Advance Purchase Agreements (Pfizer/BioNTech)
• Cotton flags the European Ombudsman's investigation into Ursula von der Leyen's undisclosed SMS messages with Pfizer's CEO Albert Bourla — still unresolved at recording. ▶ 17:32
  Sources: European Ombudsman decision OI/4/2022/PB
• The Commission awarded McKinsey a 2.5 million euro contract for a 70-page report on "manufacturing options for medical countermeasures against serious cross-border health threats" during the crisis. ▶ 18:06
  Sources: EU Commission–McKinsey contract (2022, medical countermeasures study)
• Conflict-of-interest pattern: vdL's son works at McKinsey; her husband is a senior officer of a Maastricht-region pharmaceutical company in the Pfizer network. The EU Transparency Register also shows recurring vdL meetings with Bill Gates, Global Citizen, and Open Society. ▶ 18:44
  Sources: EU Transparency Register (vdL meeting log)

Documents cited

• Pfizer C4591001 Protocol — NEJM supplementary materials
• Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
• Pfizer booster sub-study protocol (Dec 2020 amendment to C4591001) — ClinicalTrials.gov registration changes / FDA submission
• EU Advance Purchase Agreements (Pfizer/BioNTech) — European Ombudsman OI/4/2022/PB; partial redacted versions on European Commission's transparency page
• European Ombudsman decision OI/4/2022/PB (vdL–Bourla SMS) — ombudsman.europa.eu
• EU Transparency Register — Commissioner meeting logs — ec.europa.eu/transparencyregister
• EU Commission–McKinsey contract (medical countermeasures study) — EU Financial Transparency System / TED

• Find the section of the Pfizer C4591001 protocol that authorizes antipyretic use during the trial, and the data table (interim or final CSR) confirming the 3.5× imbalance in antipyretic use between vaccine and placebo arms.Anchors the strongest specific claim in the interview (~02:54): the 95% headline was confounded by symptom suppression.
• Retrieve the EU Advance Purchase Agreement(s) and procurement figures showing 4.2 billion doses ordered for the EU. Sources: European Ombudsman case file, EP COVI committee reports, leaked HJI documents.Cited at ~13:48 as proof Brussels knew boosters would be required.

  Sources she cites in the book

  • 237 Michele Rivasi (MEP) website — debrief/interview with Christine Cotton on the efficacy of the Pfizer anti-COVID vaccine (May 2022)
  • 241 European Parliament multimedia webstreaming — Special Committee on the COVID-19 pandemic (COVI), hearing of 10 October 2022
  • 289 European Parliament press room news (12 April 2022) — the Parliament's special committee on COVID-19 (COVI) begins its work
  • 290 European Parliament multimedia webstreaming — COVI committee / Policy Department A workshop, 9 March 2023
  • 291 L'Humanite (humanite.fr) — video report "Vaccins Pfizer: le scandale des SMS continue" on the von der Leyen–Bourla text messages
• Find the Pfizer booster sub-study (added to C4591001 in December 2020) — the protocol amendment, ClinicalTrials.gov record, or FDA submission cover letter.Cited at ~06:00 — proof that Pfizer was already preparing boosters at the moment of initial authorization.

  Sources she cites in the book

  • 124 FDA media/159195 — VRBPAC briefing document for the Pfizer-BioNTech COVID-19 vaccine in children 6 months through 4 years of age (June 2022), section 6.2 Uncertainties related to benefits
  • 136 FDA media/152161 — Pfizer-BioNTech submission/briefing for the COVID-19 vaccine booster (third) dose to the FDA (September 2021)
  • 137 Drugs.com / MedNews press release — "Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster" (September 2021); named in prose, no URL given
• Pull recent EU Transparency Register entries for vdL meetings with Bill Gates, Global Citizen, and Open Society Foundations; capture dates and meeting topics.Cited at ~17:32 as evidence of the influence network around the Commission's vaccine strategy.
• Archive the McKinsey-EU 2.5 million euro "medical countermeasures manufacturing options" contract (commissioning notice + final report if available).Cited at ~17:32 as exhibit A in the McKinsey-EU-pharma triangle.

  Sources she cites in the book

  • 257 McKinsey & Company — Healthcare/Our Insights article "Ten lessons from the first two years of COVID-19" (2022) ⧉ archived